Journal article
Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs
ST Diepstraten, S Young, JE La Marca, Z Wang, RM Kluck, A Strasser, GL Kelly
Cell Death and Differentiation | SPRINGERNATURE | Published : 2023
Abstract
BH3-mimetic drugs are an anti-cancer therapy that can induce apoptosis in malignant cells by directly binding and inhibiting pro-survival proteins of the BCL-2 family. The BH3-mimetic drug venetoclax, which targets BCL-2, has been approved for the treatment of chronic lymphocytic leukaemia and acute myeloid leukaemia by regulatory authorities worldwide. However, while most patients initially respond well, resistance and relapse while on this drug is an emerging and critical issue in the clinic. Though some studies have begun uncovering the factors involved in resistance to BCL-2-targeting BH3-mimetic drugs, little focus has been applied to pre-emptively tackle resistance for the next generat..
View full abstractRelated Projects (1)
Grants
Awarded by Cass Foundation
Funding Acknowledgements
This work was supported by fellowships and grants from the Australian National Health and Medical Research Council (NHMRC) (Program Grant GNT1113133 to RMK and AS, Research Fellowship GNT1116937 to AS, Project Grant GNT1143105 to AS, Ideas Grants GNT 2002618 and GNT2001201 to GLK, Synergy Grants GNT2011139 to GLK and GNT 2010275 to AS), the Leukemia & Lymphoma Society of America (Specialized Center of Research [SCOR] grant no. 7015-18 to RMK, AS and GLK), Victorian Cancer Agency (MCRF Fellowship 17028 to GLK and ECRF Fellowship 21006 to STD), CASS Foundation Grants (to STD and JELM), the estate of Anthony (Toni) Redstone OAM (AS and GLK), the Craig Perkins Cancer Research Foundation (GLK), the Dyson Bequest (GLK) and the Harry Secomb Foundation (GLK), and operational infrastructure grants through the Victorian State Government Operational Infra-structure Support (OIS) and Australian Government NHMRC Independent Research Institute Infrastructure Support (IRIIS) Schemes.